Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Pierre Fabre
Initial public offering momentum decelerated as stock prices declined last year, but even with lower valuations making M&A more attractive, the IPO market this year is expected to be active.
Plus deals involving GC Cell/Rivaara Immune, Sperogenix/Santhera, EOFlow/Zihipp, Grand/ITM, Tasly/Sutro, LegoChem/Iksuda, Nuance/Aerogen, Frontier/AffiRiS and Piramal/Yapan.
The recall, which is related to the risk fluid leaks may make the pumps shut down during use, comes only a few months after battery packs used in the pumps were recalled.
Companies like Bayer and AstraZeneca are seeing what a difference decentralization makes as CVS is rapidly expanding its clinical research business.
- Pharmacy Services, PBMs
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
- Pierre Fabre Medicament S.A.